Recent Updates
Recently added Catalysts
PMCB Positive Sentiment

PharmaCyte Biotech Reports Strong Cash and Asset Position

Friday, November 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: PharmaCyte Biotech, Inc. reported a strong financial position in its quarterly update. As of July 31, 2026, the company held total assets of approximately $36.7 million, which includes around $17.7 million in cash. Stockholders' equity was approximately $27.5 million, indicating a solid financial foundation.

Market Sentiment Analysis

POSITIVE FACTORS

  • PharmaCyte reported total assets of approximately $36.7 million.
  • The company has about $17.7 million in cash and cash equivalents.
  • Stockholders' equity reached approximately $27.5 million.

Full Press Release Details

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) today provided an update on its financial position. As reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended July 31, 2026 (PMCB’s fiscal year ends April 30), PharmaCyte held total assets of approximately $36.7 million, including approximately $17.7 million in cash and cash equivalents. Stockholders’ equity totaled approximately $27.5 million as of July 31, 2026. PharmaCyte

Frequently Asked Questions

What are PharmaCyte's total assets?

PharmaCyte's total assets are approximately $36.7 million.

How much cash does PharmaCyte hold?

PharmaCyte has about $17.7 million in cash and cash equivalents.

What is PharmaCyte's stockholders' equity?

The stockholders' equity totals approximately $27.5 million.

When does PharmaCyte's fiscal year end?

PharmaCyte's fiscal year ends on April 30.

ShareAdd on Google
Tags: PMCB PharmaCyte financial report assets cash position
Last updated: Nov 13, 2026

Biotech snapshot

Cash runway
$18M liquidity · $0M/mo burn
~67 mo
Minimal dilution risk